Form 4: AnaptysBio Director Executes Pre-Planned Stock Option Exercise and Sale

AnaptysBio Director Hollings Renton exercised 20,925 stock options at $6.93 and simultaneously sold all acquired shares for a weighted average price of approximately $23.49, generating over $348,000 in proceeds, as part of a pre-arranged trading plan.

Summary

• Director Hollings Renton of AnaptysBio, Inc. (ANAB) exercised 20,925 stock options on July 2, 2025, at an exercise price of $6.93 per share.
• Immediately following the exercise, Renton sold all 20,925 shares of common stock acquired from the option exercise.
• The sales were executed in two tranches: 7,250 shares at a weighted average price of $23.0908 (ranging from $22.425 to $23.395) and 13,675 shares at a weighted average price of $23.8232 (ranging from $23.56 to $24.015).
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Renton on March 14, 2024, designed to facilitate the orderly exercise and sale of options expiring on July 5, 2025.
• After these transactions, Mr. Renton beneficially owns 4,965 shares of common stock directly.
• Mr. Renton also holds additional options to purchase up to an aggregate of 112,051 shares of common stock, which vest according to their terms.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is routine and pre-planned, indicating no immediate negative signal. The director realized a significant profit on the options, which is positive for the individual, and still retains a substantial number of future options, indicating continued alignment with shareholder interests.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned and orderly disposition of shares rather than a reaction to new negative information.
• The sale prices of the common stock ($23.0908 and $23.8232) are significantly higher than the exercise price of $6.93, indicating a substantial profit for the director on these specific options.
• The director still holds 4,965 shares directly and additional options for 112,051 shares, indicating continued vested interest in the company's performance.

Negatives

• A director selling a significant portion of shares acquired from option exercise, even under a 10b5-1 plan, could be perceived as a reduction in direct equity exposure.

Future Outlook

The document indicates that the director holds additional stock options for 112,051 shares that will vest according to their terms, suggesting potential future exercises and sales.

Management Comments

• The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2024.
• Mr. Renton holds various stock options that are expiring in 2025 and wished to put the plan in place to facilitate the orderly exercise of such options, including the options exercised and sold under this Form 4, which have an expiration date of July 5, 2025.

Industry Context

This Form 4 filing details a routine insider transaction (exercise and sale of expiring stock options) by a director of AnaptysBio, a biotechnology company. Such transactions are common for executives managing their equity compensation and do not inherently reflect specific industry trends or competitive positioning, but rather individual financial planning.

Comparison to Industry Standards

• Insider transactions like this are standard practice across industries, particularly in biotechnology where executive compensation often includes significant equity components.
• The use of a Rule 10b5-1 plan aligns with best practices for insiders to manage their stock holdings in a pre-scheduled, compliant manner, mitigating concerns about trading on material non-public information.
• There are no specific comparable companies or projects mentioned in this transactional filing to benchmark against.

Stakeholder Impact

• Shareholders: The sale by a director, even if pre-planned, could be perceived as a slight reduction in insider ownership, but the use of a 10b5-1 plan and retention of other options mitigates significant negative impact. The profit realized by the director highlights the value creation from the stock options.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Future exercises and sales of the remaining 112,051 stock options held by Mr. Renton, as they vest according to their terms.

Key Dates

Recommendation

Keywords

ANAPTYSBIO, ANAB, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Director Transaction, Hollings Renton, Biotechnology, Pharmaceuticals